semaglutide

semaglutide is a glucagon-like peptide-1 receptor agonist medication used primarily for the treatment of type 2 diabetes and chronic weight management. Developed by the Danish pharmaceutical company Novo Nordisk, it is marketed under brand names including Ozempic, Wegovy, and Rybelsus. Its mechanism involves mimicking an incretin hormone to increase insulin secretion, decrease glucagon release, and slow gastric emptying, leading to improved glycemic control and reduced appetite.

Medical uses

semaglutide is approved by the U.S. Food and Drug Administration and the European Medicines Agency for managing type 2 diabetes mellitus, often in conjunction with diet and exercise. The higher-dose formulation, marketed as Wegovy, received regulatory approval specifically for obesity treatment in adults and adolescents. Clinical trials, such as the SUSTAIN and STEP programs, demonstrated its efficacy in significantly lowering HbA1c levels and promoting substantial weight loss compared to placebos or other agents like dulaglutide and liraglutide. It is also being investigated for potential benefits in conditions like nonalcoholic steatohepatitis and cardiovascular disease.

Pharmacology

As a GLP-1 receptor agonist, semaglutide binds to and activates the GLP-1 receptor in the pancreas, brain, and gastrointestinal tract. This action stimulates glucose-dependent insulin secretion from pancreatic beta cells while suppressing the release of glucagon from pancreatic alpha cells. It also markedly delays gastric emptying and acts on hypothalamic centers to promote satiety. The molecule is structurally modified with a fatty acid side chain, which promotes binding to albumin, resulting in an extended half-life of approximately one week, allowing for once-weekly subcutaneous or once-daily oral dosing.

Adverse effects

The most common adverse reactions involve the gastrointestinal system, including nausea, vomiting, diarrhea, abdominal pain, and constipation, which are often transient and dose-dependent. There is a potential risk of medullary thyroid carcinoma, as seen in rodent studies, leading to a boxed warning against use in patients with a personal or family history of multiple endocrine neoplasia type 2 or thyroid cancer. Other warnings include the risk of pancreatitis, diabetic retinopathy complications, acute kidney injury, and gallbladder disease. Hypoglycemia risk increases when combined with other therapies like sulfonylureas or insulin.

History

semaglutide originated from research into incretin-based therapies at Novo Nordisk's facilities in Bagsværd, Denmark. Its development built upon the success of the company's earlier GLP-1 analog, liraglutide. The drug's clinical development program began in the early 2010s, leading to its first regulatory approval for type 2 diabetes by the FDA in 2017 under the brand Ozempic. The oral formulation, Rybelsus, was approved in 2019, representing a significant advancement in peptide delivery. Approval for chronic weight management under the brand Wegovy followed in 2021 in the United States and subsequently in the European Union.

Society and culture

The widespread adoption of semaglutide, particularly for weight loss, has had a substantial impact on popular culture and the pharmaceutical industry, contributing to significant revenue growth for Novo Nordisk. High demand has periodically led to supply shortages, as reported by the American Society of Health-System Pharmacists. Its use has sparked extensive media coverage, discussions on the ethics of cosmetic weight loss, and debates about insurance coverage and accessibility within healthcare systems like the National Health Service. The drug's success has also intensified competition in the obesity medicine market, involving other companies like Eli Lilly and Company, developer of tirzepatide. Category:Antidiabetic drugs Category:GLP-1 receptor agonists Category:Novo Nordisk